Abstract: The subject of the present invention is specific lipidesters of halogenated nucleotides of the following formula wherein R1, R2, R3, X and Y are defined as described herein and salts thereof, said compounds have anti-cancer properties; pharmaceutical compositions containing the compounds, a method of synthesizing the compounds, and a method of using the compounds for treating malignant tumors.

Abstract: A membranous enzyme not yet described in the state-of-the-art can be extracted from cellular membrane fractions of blood leukocytes or monocytes/macrophages. Also disclosed is the use of substrates of this enzyme to prepare medicaments that contain these substrates as pharmaceutical active substance. These medicaments are useful to direct pharmacologically active substances to target cells and to enrich target cells with said substances. Also disclosed are in-vitro research systems containing this enzyme used to detect other substrates of this enzyme.

Abstract: The subject of the present invention are specific lipidesters of halogenated-adenine nucleotides and the use of such lipidesters in the treatment of tumors.

Abstract: The present invention relates to drugs containing phospholipid derivatives preferably of non-natural nucleosides corresponding to general formula I: in which R1 represents an alkyl chain with 10-14 carbon atoms, R2 represents an alkyl chain with 8-12 carbon atoms, n represents an integer equal to 0 to 2, R3 represents a hydroxy group, R4 and R5 represent hydrogen, and B represents 5-fluorouracil, for use as antitumoral or antiproliferative active ingredients for the prophylaxis and/or curative, palliative or supportive treatment of tumor diseases or neoplasias, such as for example carcinomas, sarcomas, lymphomas or leukemias, both as therapeutic or prophylactic agents for monotherapy and in free or fixed combination with other modalities of prophylaxis or therapy.

Abstract: A membranous enzyme not yet described in the state-of-the-art can be extracted from cellular membrane fractions of blood leukocytes or monocytes/macrophages. Also disclosed is the use of substrates of this enzyme to prepare medicaments that contain these substrates as pharmaceutical active substance. These medicaments are useful to direct pharmacologically active substances to target cells and to enrich target cells with said substances. Also disclosed are in-vitro research systems containing this enzyme used to detect other substrates of this enzyme.

Abstract: A membranous enzyme not yet described in the state-of-the-art can be extracted from cellular membrane fractions of blood leukocytes or monocytes/macrophages. Also disclosed is the use of substrates of this enzyme to prepare medicaments that contain these substrates as pharmaceutical active substance. These medicaments are useful to direct pharmacologically active substances to target cells and to enrich target cells with said substances. Also disclosed are in-vitro research systems containing this enzyme used to detect other substrates of this enzyme.

Abstract: A plastic pipe based on polyolefins is provided, which pipe, compared with single-layer pipes of polyolefins, has improved barrier action against (petro)chemical materials, in particular against methanol-containing fuels. This is achieved by a multilayer plastic pipe which comprises the following layers: I. at least one layer based on a polyolefin, II. at least one layer based on a thermoplastic polyester, bonded via III. a layer between them of a suitable coupling agent which contains reactive groups, with adjacent layers being cohesively bonded to one another. The invention makes it possible to obtain plastic pipes having the desired improved property profile.

Abstract: The present invention concerns new phospholipid derivatives of nucleosides of the general formula (I) in which R1 represents a straight-chained or branched, saturated or unsaturated aliphatic residue with 9-14 carbon atoms which can optionally be substituted once or several times; R2 can represent a straight-chained or branched, saturated or unsaturated aliphatic residue with 8-12 carbon atoms which can optionally be substituted once or several times; m is 2 or 3; A can represent a methylene group or an oxygen; Nuc can be a nucleoside or a residue derived from a nucleoside derivative; and tautomers thereof and their physiologically tolerated salts of inorganic and organic acids and bases as well as pharmaceutical preparations containing these compounds.

Abstract: The present invention concerns new immunosuppressive and antiviral pharmaceutical agents using lipid alcohols of the general formulae I and II in which R1 represents a straight-chained or branched, saturated or unsaturated alkyl chain with 1-30 carbon atoms which can optionally be substituted once or several times by halogen, C1-C6 alkoxy, C1-C6 alkylmercapto, C1-C6 alkoxycarbonyl, carboxy, C1-C6 alkylsulfinyl or C1-C6 alkylsulfonyl groups, R2 represents hydrogen, a straight-chained or branched, saturated or unsaturated alkyl chain with 1-20 carbon atoms which can optionally be substituted once or several times by halogen, C1-C6 alkoxy, C1-C6 alkylmercapto, C1-C6 alkoxycarbonyl or C1-C6 alkylsulfonyl groups, X represents a valency dash, oxicarbonyl, carbonyloxy, amidocarbonyl, carbonylamido, oxygen, sulphur, a sulfinyl or sulfonyl group Y represents a valency dash, oxicarbonyl, carbonyloxy, amidocarbonyl, carbonylamido, oxygen, sulphur, a sulfinyl or sulfonyl group n represents an integ

Abstract: A fuel injection valve for internal combustion engines, having a valve member that is displaceable axially outward counter to a restoring force in a bore of a valve body. On an end toward the combustion chamber, the valve member has a closing head. The closing head protrudes from the bore and forms a valve closing member and on a side toward the valve body has a valve sealing face. The valve closing member cooperates with a valve seat face, disposed on a face end toward the combustion chamber of the valve body. The valve closing member at least one injection opening on the closing head. The injection opening originating at a pressure chamber and outlet opening being covered, in the closing position of the valve member, by the valve body and being uncovered upon an outward-oriented opening stroke. A two-stage hydraulic stroke stop, which limits the opening stroke of the valve member and is embodied as a hydraulic damping chamber with a relief line that can be opened.

Abstract: The present invention concerns new lipid derivatives of phosphonocarboxylic acids of the general formula I, ##STR1## in which the meaning of the symbols is elucidated in the description, tautomers thereof and their physiologically tolerated esters and salts of inorganic or organic bases as well as processes for the production thereof and pharmaceutical agents containing these compounds.

Abstract: The present invention is directed to new phospholipid derivatives of acyclovir and ganciclovir that link a lipid moiety, which represents a substituted C3 backbone, to acyclovir or ganciclovir via phosphate or thiophosphate. The compounds are particularly suitable for the therapy of viral infections.

Abstract: The present invention is directed to new nucleoside monophosphate derivatives of lipid ester residues of general formula (I) ##STR1## wherein R.sup.1 represents an optionally substituted alkyl chain having 1-20 carbon atoms;R.sup.2 represents hydrogen, an optionally substituted alkyl chain having 1-20 carbon atoms;R.sup.3, R.sup.4 and R.sup.5 represent hydrogen, hydroxy, azido, amino, cyano, or halogen;X represents a valence dash, oxygen, sulfur, a sulfinyl or sulfonyl group;Y represents a valence dash, an oxygen or sulfur atom;B represents a purine and/or pyrimidine base;with the proviso that at least one of the residues R.sup.3 or R.sup.5 is hydrogen;to their tautomers and their physiologically acceptable salts of inorganic and organic acids and/or bases, as well as to processes for their preparation, and to drugs containing said compounds.

Abstract: The present invention concerns new lipid derivatives of phosphonocarboxylic acids of the general formula I, ##STR1## in which the meaning of the symbols is elucidated in the description, tautomers thereof and their physiologically tolerated salts of inorganic and organic bases as well as processes for the production thereof and pharmaceutical agents containing these compounds.

Abstract: The present invention provides a pharmaceutical combination preparation, wherein it contains at least two active materials, the first active material being an inhibitor of protein kinase C and the other active material having an anti-neoplastic action, as well as pharmacologically acceptable carriers and adjuvants.

Abstract: Compounds of the formula I ##STR1## in which R.sub.1 and R.sub.2 represent a possibly substituted C.sub.8 -C.sub.15 -alkyl chain, n the number 0, 1 or 2 and A the residue of a nucleoside, processes for their preparation, as well as antiviral medicaments which contain these compounds.

Abstract: The present invention provides a method of inhibiting protein kinase C in a mammal having a tumor system which contains protein kinase C, which mammal is undergoing cytostatic therapy. The method comprises administering to the mammal a protein kinase C inhibitor.

Abstract: Liponucleotides containing an ether linkage in the 2-position and a thioether, sulfoxide, or sulfone linkage in the 3-position. The nucleoside component of said liponucleotide is AZT or 3'-deoxy-3'-fluorothymidine. These compounds exhibit antiviral activity.

Abstract: The present invention provides [3-(C.sub.16 -C.sub.18)-alkaesulphinyl- and -sulphonyl-2-methoxy-methylpropyl]-(2-trimethylammonioethyl) phosphates having superior anti-tumor activity.

Abstract: A plastic pipe having improved resistance, inter alia, to methanol-containing fuels and improved mechanical properties, comprising at least:(I) an outer layer,(III) an inner layer comprising a moulding composition based on polyvinylidene fluoride, and(II) an intermediate layer disposed between said inner layer (I) and said outer layer (III) comprising a moulding composition based on a mixture of(a) polyamide, and(b) polyglutarimide,wherein the adjacent layers (I) to (III) are each adhesively bonded to one another.